| Number: 201204071 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma |
| Description: The purpose of this research study is to find the maximum tolerated dose for Abraxane as well as discover what side effects are associated with its use in patients with lymphoma and how the disease responds to Abraxane....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201101864 |
Principal Investigator: Stockerl-Goldstein, Keith |
| Title: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma |
| Description: You may be invited to participate in a research study to treat non-Hodgkin’s lymphoma. The treatment plan consists of an autologous hematopoietic (blood) cell transplant followed by a non-myeloablative allogeneic transplantation (transplant from another individual). An autologous transplant is don...MORE |
| ___________________________________________________________________________________________________ |
| Number: P2C 9271 |
Principal Investigator: Bartlett, Nancy |
| Title: Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma |
| Description: The purpose of this study is to find out what effects, good and/or bad, ibrutinib has on the patient and their follicular lymphoma. This study focuses on patients who have follicular lymphoma that is no longer responding to rituximab treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU S1106 |
Principal Investigator: Bartlett, Nancy |
| Title: A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. RBendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients = 65 Years of Age with Previously Untreated Mantle Cell Lymphoma |
| Description: This is an investigational study that is being done to find out what effects, good or bad, a combination of drugs called “R-HCVAD/MTX/ARA-C” versus “R-bendamustine” followed by a stem cell transplant has on patients and their mantle cell lymphoma....MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU S1001 |
Principal Investigator: Bartlett, Nancy |
| Title: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) (S1001) |
| Description: This study uses a radiologic test called a PET/CT scan to determine treatment after initial doses of a standard FDA approved chemotherapy regimen called "R-CHOP". The purpose of the study is to give more intensive treatment to patients whose PET/CT scan shows that they are at a greater chance of sti...MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU 9177 |
Principal Investigator: Bartlett, Nancy |
| Title: Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma (9177) |
| Description: The purpose of this research study is to compare the good and/or bad effects of an investigational approach to treating certain types of lymphoma....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB CTSU E1411 |
Principal Investigator: Bartlett, Nancy |
| Title: Intergroup Randomized Phase II 4 Arm Study In Patients > or equal to 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation; Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation, Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation |
| Description: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and lenalidomide in treating previously untreated older patients with mantle cell lymphoma....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 51101 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma |
| Description: The purpose of this research study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 50904 |
Principal Investigator: Bartlett, Nancy |
| Title: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lymphoma |
| Description: The purpose of this research study is to find out what effects (good and/or bad) treatment with the combination of ofatumumab and bendamustine or the combination of ofatumumab, bendamustine, and bortezomib has on patients and their lymphoma....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 50901 |
Principal Investigator: Bartlett, Nancy |
| Title: A Phase II Trial of Ofatumumab (CALGB IND# 112390) in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL) |
| Description: The purpose of this study is to find out what effects, good and/or bad, the drug ofatumumab has on patients and their NHL....MORE |
| ___________________________________________________________________________________________________ |
| Number: AMC 075 |
Principal Investigator: Ratner, Lee |
| Title: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma |
| Description: This study is being conducted because scientists think that adding vorinostat therapy may enhance the effectiveness of standard chemotherapy plus rituximab in certain types of lymphoma, and may also have a positive effect against HIV and other viruses in our bodies which can cause lymphoma....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201304114 |
Principal Investigator: Bartlett, Nancy |
| Title: An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma |
| Description: The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma with early access to an investigational drug called ibrutinib and to collect safety information about the drug....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201304035 |
Principal Investigator: Cashen, Amanda |
| Title: A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients with Advanced Cancers |
| Description: The purpose of this study is to test how well study patients tolerate different doses of ISIS 481464 (the study drug) and to find out what effects, good or bad, ISIS 481464 has on the cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301089 |
Principal Investigator: Bartlett, Nancy |
| Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PCYC-1115-CA) |
| Description: The purpose of this study is to see whether or not the study drug (PCI-32765) works and is safe in patients (65 years and older) with treatment naïve CLL/SLL compared to chlorambucil....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301088 |
Principal Investigator: Bartlett, Nancy |
| Title: An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil) (PCYC-1116-CA) |
| Description: The purpose of this study is to provide patients who previously participatecd in the PCYC-115-CA study access to the investigational drug, PCI-32765 or alternative treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201212100 |
Principal Investigator: Bartlett, Nancy |
| Title: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion |
| Description: The purpose of this study is to test whether or not the investigational study drug, PCI-32765(ibrutinib) works and is safe in patients with CLL / SLL with 17p deletion....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209095 |
Principal Investigator: Ratner, Lee |
| Title: Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) |
| Description: The main purpose of this study is to determine if KW-0761 will work against adult T-cell leukemia-lymphoma that has failed to respond to other treatments, and to evaluate its side effects....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201208155 |
Principal Investigator: Carson, Kenneth |
| Title: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma |
| Description: The purpose of this research study is to determine if KW-0761 will work against cutaneous T-cell lymphoma that has failed to respond to other treatments, and to evaluate its side effects....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201208075 |
Principal Investigator: Bartlett, Nancy |
| Title: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas SGN35-014) |
| Description: This is a clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201207089 |
Principal Investigator: Bartlett, Nancy |
| Title: Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Description: The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201205103 |
Principal Investigator: DiPersio, John |
| Title: Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies |
| Description: The main purpose of this clinical research study is to find the highest tolerable dose of the study drug KB004, which is being tested as a possible therapy for people with different
types of blood cancer (leukemia
as well as other blood cancers). This study will also explore whether KB004 is safe fo...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201204004 |
Principal Investigator: Bartlett, Nancy |
| Title: A Phase 2 Randomized Open-label Study of MEDI-551 in Adults with Relapsed or Refractory DLBCL |
| Description: The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for autologous stem cell transplant (ASCT), has s...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201201017 |
Principal Investigator: Bartlett, Nancy |
| Title: A phase 3 open-label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (cc-5013) versus rituximab plus chemotherapy followed by Rituximab in subjects with previously untreated follicular lymphoma |
| Description: The purpose of this study is to find out if a drug called lenalidomide when given along with rituximab can help to control the disease and also increase the length of response (complete or partial response) compared to the current standard of care which is rituximab plus chemotherapy treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201110246 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Description: The purpose of this study is to learn more about how effective the investigational drug SAR245409 is for treating cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201109213 |
Principal Investigator: Bartlett, Nancy |
| Title: A Phase I Study of Pf-05082566 as a Single Agent in Patients with Advanced Cancer, And in Combination with Rituximab in Patients with Non-Hodgkin’s Lymphoma (NHL) |
| Description: The purpose of this research study is to learn about the effects of the study drug, PF-05082566, and to find the best dose for treating Non-Hodgkin’s lymphoma....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201109194 |
Principal Investigator: Martin, Ann |
| Title: Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma |
| ___________________________________________________________________________________________________ |
| Number: 201107208 |
Principal Investigator: Bartlett, Nancy |
| Title: An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma |
| Description: The purpose of this clinical research study is to test if the study drug AEB071 has any activity against a certain type of Diffuse Large B-Cell Lymphoma. It also will help to determine the highest dose of AEB071 that can be given safely without unacceptable side effects. The study will also examin...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201106427 |
Principal Investigator: Bartlett, Nancy |
| Title: A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL) |
| Description: The purpose of this research study is to test if brentuximab vedotin (SGN-35) has an effect on cancer in patients with non Hodgkin lymphoma. The side effects of SGN-35 in patients with non Hodgkin lymphoma will also be studied....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201103345 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: A Phase I Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia |
| Description: The purpose of this study is to see if an investigational drug named CAL-101 in combination with rituximab and bendamustine is safe to give to people with certain types of cancer and to see how it affects patients and their cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201101897 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients with Hematologic Malignancies |
| Description: The purpose of this study is to determine the dose of the investigational drug CAL-101 at which patients will develop side effects and to see if it is safe to give to people with certain types of cancer and to see how it affects patients and their cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201101751 |
Principal Investigator: Carson, Kenneth |
| Title: Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma |
| Description: The purpose of this study is to collect demographic information (e.g., age, gender) on patients as well as information on patients’ disease (e.g., type of cancer, extent of the cancer), treatment, and outcome. This information may help healthcare professionals better understand Peripheral T-Cell Ly...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108251 |
Principal Investigator: Cashen, Amanda |
| Title: Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of Lymphoid Malignancies |
| ___________________________________________________________________________________________________ |